These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17632536)

  • 1. The pharmaceutical industry at risk: how excessive government regulation stifles innovation.
    Epstein RA
    Clin Pharmacol Ther; 2007 Aug; 82(2):131-2. PubMed ID: 17632536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the prohibition of conflicts of interest in pharmaceutical regulation: precautionary limits and permissive challenges. A commentary on Sismondo (66:9, 2008, 1909-14) and O'Donovan and Lexchin.
    Abraham J
    Soc Sci Med; 2010 Mar; 70(5):648-51. PubMed ID: 20056525
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharma on the hot seat.
    Huberfeld N
    J Health Law; 2007; 40(2):241-65. PubMed ID: 17849829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970.
    Tobbell DA
    Bull Hist Med; 2008; 82(4):878-912. PubMed ID: 19075387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries.
    Mittra J; Tait J; Wield D
    Trends Biotechnol; 2011 Mar; 29(3):105-9. PubMed ID: 21163543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical innovation gets a little help from new friends.
    Munos BH
    Sci Transl Med; 2013 Jan; 5(168):168ed1. PubMed ID: 23325797
    [No Abstract]   [Full Text] [Related]  

  • 7. A call for sharing: adapting pharmaceutical research to new realities.
    Munos BH; Chin WW
    Sci Transl Med; 2009 Dec; 1(9):9cm8. PubMed ID: 20368187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critique of emerging European legislation in the pharmaceutical industry: a clinical trials analysis.
    Murray E; McAdam R; Burke MT
    Int J Health Care Qual Assur Inc Leadersh Health Serv; 2004; 17(7):389-93. PubMed ID: 15552394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Price controls and global pharmaceutical progress.
    Scherer FM
    Health Aff (Millwood); 2009; 28(1):w161-4. PubMed ID: 19088103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Austerity vs. growth--the impact of the current financial crisis on pharmaceutical innovation.
    Sharma D; Martini LG
    Int J Pharm; 2013 Feb; 443(1-2):242-4. PubMed ID: 23296153
    [No Abstract]   [Full Text] [Related]  

  • 11. The undiscovered Argentine pharmaceutical market.
    Felix PF; Thomas RK; Pol LG
    Mark Health Serv; 2001; 21(4):12-6. PubMed ID: 11763647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

  • 13. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical regulation in Greece at the crossroad of change: economic, political and constitutional considerations for a new regulatory paradigm.
    Contiades X; Golna C; Souliotis K
    Health Policy; 2007 Jun; 82(1):116-29. PubMed ID: 17049667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimizing the discovery organization for innovation.
    Sams-Dodd F
    Drug Discov Today; 2005 Aug; 10(15):1049-56. PubMed ID: 16055021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interview with Dr Richard Barker, Director General of the Association of the British Pharmaceutical Industry.
    Barker R
    Future Med Chem; 2009 Jun; 1(3):421-6. PubMed ID: 21426122
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk-based capital guidelines give incentive to capitate.
    Capitation Manag Rep; 2003 Jan; 10(1):3-5. PubMed ID: 12575516
    [No Abstract]   [Full Text] [Related]  

  • 19. Strategic alliance management: lessons learned from the Bayer-Millennium collaboration.
    Ziegelbauer K; Farquhar R
    Drug Discov Today; 2004 Oct; 9(20):864-8. PubMed ID: 15475317
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.